Kevin
Williams has written a key article for BioPharm International, titled “The
Emerging View of Endotoxin as an IIRMI.” This concerns the recognition that
microbial artifacts are capable of modulating the mammalian immune system is an
emerging view of biologic drug contamination control testing.
Here
is an extract:
“The
recognition that microbial artifacts are capable of modulating the mammalian
immune system is an emerging view of biologic drug contamination control
testing. The term IIRMI, or “innate immune response modulating impurity,” has
been coined. It is important to
recognize that pyrogenicity is only one potential risk of endotoxin
contamination and that immune activation is an inherent property of endotoxin,
even in the absence of pyrogenicity. Immune stimulation of biologics is
undesirable, as it can stimulate anti-drug antibodies against administered
recombinant proteins. Historically, many methods have been used to “detoxify”
endotoxin to remove the pyrogenicity of endotoxin while retaining its immune
stimulation properties for adjuvant use in vaccines. This article gives a broad
perspective for understanding potential risks from low endotoxin recovery (LER)
and other potential detoxification methods and presents a new paradigm to help
drive future testing.”
Posted by Dr. Tim Sandle
No comments:
Post a Comment
Pharmaceutical Microbiology Resources